Prosfora Technologies

Prosfora Technologies is a pre-clinical stage biotechnology company specializing in the development of next-generation targeted protein degradation (TPD) therapeutics. The company's proprietary platform leverages the cell's natural chaperone machinery to selectively eliminate disease-causing proteins that have historically been considered undruggable. By utilizing bifunctional small molecules, Prosfora aims to treat various forms of cancer, with a primary focus on targeting difficult mutations such as K-Ras G12D. The company originated from research conducted at the Icahn School of Medicine at Mount Sinai and is focused on expanding the scope of TPD beyond traditional E3 ligase recruitment. This approach potentially offers a way to degrade proteins that are not amenable to standard PROTAC technologies.